

25 APR 2003

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

162162

(43) International Publication Date
2 May 2002 (02.05.2002)

PCT

(10) International Publication Number
WO 02/034754 A3(51) International Patent Classification⁷: **C07D 498/00**,
413/14, 413/12, A61K 31/445, A61P 25/24

(21) International Application Number: PCT/EP01/12344

(22) International Filing Date: 22 October 2001 (22.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0026224.6 26 October 2000 (26.10.2000) GB
0111858.7 15 May 2001 (15.05.2001) GB(71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM P.L.C. [GB/GB]; New
Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **JOHNSON, Christopher, Norbert** [GB/GB]; GlaxoSmithKline Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). **RAMI, Harshad, Kantilal** [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). **STEMP,**Geoffrey [GB/GB]; GlaxoSmithKline Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). **THEWLIS, Kevin** [GB/GB]; GlaxoSmithKline Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). **THOMPSON, Mervyn** [GB/GB]; GlaxoSmithKline Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). **VONG, Antonio, Kuok, Keong** [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB).(74) Agent: **FILLER, Wendy, Anne**; SmithKline Beecham, Corporate Intellectual Property, 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European

[Continued on next page]

(54) Title: BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE

(57) Abstract: The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein Ar is phenyl, naphthyl, a monocyclic heteroaromatic group or a bicyclic heteroaromatic group, said Ar group being optionally substituted by 1-4 substituents, which may be the same or different, and which are selected from the group consisting of: halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, C₁₋₆alkyl, trifluoromethanesulfonyloxy, pentafluoroethyl, C₁₋₆alkoxy, arylC₁₋₆alkoxy, C₁₋₆alkylthio,

C₁₋₆alkoxyC₁₋₆alkyl, C₃₋₇cycloalkylC₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkoxycarbonyl, C₁₋₆alkylsulfonyl, C₁₋₆alkylsulfinyl, C₁₋₆alkylsulfonyloxy, C₁₋₆alkylsulfonylC₁₋₆alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC₁₋₆alkyl, C₁₋₆alkylsulfonamido, C₁₋₆alkylamido, C₁₋₆alkylsulfonamidoC₁₋₆alkyl, C₁₋₆alkylamidoC₁₋₆alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC₁₋₆alkyl, arylcarboxamidoC₁₋₆alkyl, aroyl, aroylC₁₋₆alkyl, arylC₁₋₆alkanoyl, a group R³OCO(CH₂)_s, R³CON(R⁴)(CH₂)_s, R³R⁴NCO(CH₂)_s or R³R⁴NSO₂(CH₂)_s where each of R³ and R⁴ independently represents a hydrogen atom or C₁₋₆alkyl or R³ and R⁴ form part of a C₃₋₆azacycloalkane or C₃₋₆(2-oxo)azacycloalkane ring and s represents zero or an integer from 1 to 4, and a group Ar¹ Z, wherein Z represents a single bond, O, S or CH₂ and Ar¹ represents a phenyl or a monocyclic heteroaromatic group, said Ar¹ group being optionally substituted by 1-3 substituents, which may be the same or different, and which are selected from the group consisting of a halogen, hydroxy, cyano, trifluoromethyl, C₁₋₆alkyl, C₁₋₆alkoxy or C₁₋₆alkanoyl; when Ar is a phenyl or a monocyclic heteroaromatic group, substituents positioned ortho to one another may be linked to form a 5- or 6-membered ring; R¹ is hydrogen, C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆alkynyl or arylC₁₋₆alkyl; R² is halogen, C₁₋₆alkyl, cyano, CF₃, C₁₋₆alkanoyl, C₁₋₆alkoxy or hydroxy; X is CH or N; Y is a single bond, O, or C=O; p is 0, 1 or 2; r is 0, 1, 2 or 3; m is 2, 3 or 4; n and q are independently 1 or 2. Processes for preparing the compounds, pharmaceutical compositions containing them and their use as medicaments for various CNS disorders, including depression and/or anxiety, are also disclosed.

WO 02/034754 A3



ACTION

patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
11 July 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.